销售代表（肿瘤-山东）

中科微智（北京）生物科技有限公司

Chinese microbiome company founded on 4 November 2021 in Haidian district, Beijing with 13.12 million yuan of registered capital, designated a high-tech enterprise and a specialised and innovative small and medium enterprise. Researches, develops and commercialises microecological preparations, live biotherapeutic products and microbiome solutions targeting the gut-brain axis, drawing on close to a decade of research and its own large proprietary strain library and high-throughput anaerobic strain isolation, screening and formulation technology. Its research team comes from the Chinese Academy of Sciences, Tsinghua, Peking University, China Pharmaceutical University, Harvard Medical School, Yale and New York University, and its probiotic brand BL-11 completed a Series A round in January 2025.